Topic
Oncology
14 stories about Oncology that passed the news check, newest first.
Research ·
South African trial tests off-the-shelf killer cells against lymphoma
South African researchers are running a trial of off-the-shelf immune cells against lymphoma that has returned or resisted treatment
Medical Xpress - latest medical and health news stories
Launch ·
FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer
On September 9, 2025, the FDA approved the gemcitabine intravesical system, marketed as Inlexzo by Janssen Biotech, Inc.
What's New: Drugs RSS Feed
Launch ·
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer
On December 12, 2025, the FDA approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone.
What's New: Drugs RSS Feed
News ·
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
On April 18, 2024, the FDA approved alectinib (Alecensa, Genentech) as adjuvant treatment following tumor resection.
What's New: Drugs RSS Feed
Launch ·
FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations
On September 19, 2024, the FDA approved amivantamab-vmjw (Rybrevant, Janssen Biotech) with carboplatin and pemetrexed.
What's New: Drugs RSS Feed
Policy ·
FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications
The FDA approved amivantamab-vmjw (Rybrevant, Janssen Biotech) with carboplatin and pemetrexed.
What's New: Drugs RSS Feed
Launch ·
FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection
The FDA approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech) for subcutaneous injection.
What's New: Drugs RSS Feed
Launch ·
FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma
On December 13, 2024, the FDA approved cosibelimab-ipdl (Unloxcyt) from Checkpoint Therapeutics.
What's New: Drugs RSS Feed
Launch ·
FDA approves durvalumab for limited-stage small cell lung cancer
On December 4, 2024, the FDA approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer.
What's New: Drugs RSS Feed
Launch ·
FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer
On December 18, 2024, the FDA approved ensartinib (brand name Ensacove, from Xcovery Holdings, Inc.).
What's New: Drugs RSS Feed
Launch ·
FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma
The FDA approved erdafitinib (Balversa, Janssen Biotech) on January 19, 2024.
What's New: Drugs RSS Feed
Launch ·
FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer
On October 10, 2024, the FDA approved inavolisib (Itovebi, Genentech) with palbociclib and fulvestrant.
What's New: Drugs RSS Feed
Policy ·
[World Report] India to cap the cost of 137 cancer drugs
India's National Pharmaceutical Pricing Authority will limit trade margins on many life-saving drugs.
thelancet.com
Research ·
DNA 'switch' uncovers new brake on breast cancer growth
Researchers at Adelaide University have identified a DNA "switch" that helps the body stop the growth of the most common form of breast cancer.
Medical Xpress - latest medical and health news stories